HC Wainwright Has Positive Forecast for BEAM Q2 Earnings

Beam Therapeutics Inc. (NASDAQ:BEAM) – HC Wainwright upped their Q2 2025 earnings per share (EPS) estimates for shares of Beam Therapeutics in a research note issued on Wednesday, May 7th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($0.78) for the quarter, up from their previous forecast of ($0.94). HC Wainwright currently has a “Buy” rating and a $80.00 target price on the stock. The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.57) per share. HC Wainwright also issued estimates for Beam Therapeutics’ Q3 2025 earnings at ($0.78) EPS, Q4 2025 earnings at ($0.79) EPS, FY2025 earnings at ($3.54) EPS, Q1 2026 earnings at ($0.75) EPS, Q2 2026 earnings at ($0.76) EPS, Q3 2026 earnings at ($0.76) EPS, Q4 2026 earnings at ($0.74) EPS, FY2026 earnings at ($3.00) EPS, FY2027 earnings at ($2.75) EPS, FY2028 earnings at ($1.77) EPS and FY2029 earnings at ($1.34) EPS.

A number of other brokerages also recently commented on BEAM. Scotiabank raised shares of Beam Therapeutics from a “sector perform” rating to a “sector outperform” rating and set a $40.00 price objective for the company in a research report on Monday, March 10th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Beam Therapeutics in a research note on Wednesday, March 12th. Barclays dropped their price target on Beam Therapeutics from $31.00 to $25.00 and set an “equal weight” rating on the stock in a research note on Wednesday, May 7th. Bank of America raised Beam Therapeutics from a “neutral” rating to a “buy” rating and set a $42.00 price target for the company in a report on Friday, March 28th. Finally, Guggenheim decreased their price objective on shares of Beam Therapeutics from $78.00 to $55.00 and set a “buy” rating on the stock in a report on Wednesday, May 7th. Two analysts have rated the stock with a hold rating, eleven have given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Beam Therapeutics has a consensus rating of “Buy” and an average target price of $48.75.

Beam Therapeutics Trading Down 1.0%

NASDAQ BEAM opened at $18.05 on Monday. Beam Therapeutics has a 12 month low of $13.53 and a 12 month high of $35.25. The stock has a 50 day moving average of $19.92 and a 200-day moving average of $24.33. The company has a market cap of $1.82 billion, a PE ratio of -10.26 and a beta of 2.35.

Beam Therapeutics (NASDAQ:BEAM) last posted its quarterly earnings results on Tuesday, May 6th. The company reported ($1.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.13). Beam Therapeutics had a negative net margin of 41.07% and a negative return on equity of 16.22%. The company had revenue of $7.47 million during the quarter, compared to the consensus estimate of $14.69 million. During the same quarter in the prior year, the business earned ($1.21) earnings per share. The firm’s revenue for the quarter was up 1.4% compared to the same quarter last year.

Insider Activity at Beam Therapeutics

In other Beam Therapeutics news, CEO John M. Evans sold 30,663 shares of the business’s stock in a transaction dated Tuesday, April 1st. The shares were sold at an average price of $18.35, for a total value of $562,666.05. Following the completion of the sale, the chief executive officer now owns 986,249 shares of the company’s stock, valued at $18,097,669.15. The trade was a 3.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Christine Bellon sold 5,674 shares of the stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $18.35, for a total transaction of $104,117.90. Following the transaction, the insider now owns 117,294 shares in the company, valued at approximately $2,152,344.90. The trade was a 4.61% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 43,771 shares of company stock worth $803,198. Corporate insiders own 4.20% of the company’s stock.

Hedge Funds Weigh In On Beam Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. ARK Investment Management LLC increased its position in shares of Beam Therapeutics by 20.0% in the first quarter. ARK Investment Management LLC now owns 8,480,089 shares of the company’s stock worth $165,616,000 after purchasing an additional 1,412,060 shares during the period. Vanguard Group Inc. lifted its stake in Beam Therapeutics by 16.4% in the 1st quarter. Vanguard Group Inc. now owns 8,871,292 shares of the company’s stock valued at $173,256,000 after purchasing an additional 1,249,303 shares during the last quarter. Casdin Capital LLC lifted its stake in Beam Therapeutics by 61.3% in the 4th quarter. Casdin Capital LLC now owns 1,250,000 shares of the company’s stock valued at $31,000,000 after purchasing an additional 475,000 shares during the last quarter. Nikko Asset Management Americas Inc. grew its stake in shares of Beam Therapeutics by 11.4% during the fourth quarter. Nikko Asset Management Americas Inc. now owns 3,957,611 shares of the company’s stock worth $98,109,000 after buying an additional 404,782 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. grew its stake in shares of Beam Therapeutics by 11.4% during the fourth quarter. Sumitomo Mitsui Trust Group Inc. now owns 3,957,611 shares of the company’s stock worth $98,149,000 after buying an additional 404,782 shares during the last quarter. Institutional investors own 99.68% of the company’s stock.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.